Have a personal or library account? Click to login
Primidone Intolerance in Essential tremor: Is it More than Just Age? Cover

Primidone Intolerance in Essential tremor: Is it More than Just Age?

Tremor and Other Hyperkinetic Movements
Volume 11 (2021): Issue 1
By: Abhishek Lenka and  Elan D. Louis  
Open Access
|Dec 2021

References

  1. 1Louis ED, Ottman R. How Many People in the USA Have Essential Tremor? Deriving a Population Estimate Based on Epidemiological Data. Tremor and Other Hyperkinetic Movements. 2014; 4: 259. DOI: 10.5334/tohm.198
    Back to article
  2. 2Louis ED, McCreary M. How Common is Essential Tremor? Update on the Worldwide Prevalence of Essential Tremor. Tremor and Other Hyperkinetic Movements; 11. Epub ahead of print 9 July 2021. DOI: 10.5334/tohm.632
    Back to article
  3. 3Ferreira JJ, Mestre TA, Lyons KE, et al. MDS evidence-based review of treatments for essential tremor. Movement Disorders 2019; 34: 950–958. DOI: 10.1002/mds.27700
    Back to article
  4. 4Louis ED, Rios E, Henchcliffe C. How are we doing with the treatment of essential tremor (ET)?: Persistence of patients with ETon medication: Data from 528 patients in three settings. Eur J Neurol 2010; 17: 882–884. DOI: 10.1111/j.1468-1331.2009.02926.x
    Back to article
  5. 5O’Brien M, Upton AR, Toseland PA. Benign familial tremor treated with primidone. Br Med J (Clin Res Ed) 1981; 282: 178–180. DOI: 10.1136/bmj.282.6259.178
    Back to article
  6. 6Chakrabarti A, Pearce JMS. Essential tremor: Response to primidone. Journal of Neurology Neurosurgery and Psychiatry 1981; 44: 650. DOI: 10.1136/jnnp.44.7.650
    Back to article
  7. 7Nida A, Alston J, Schweinfurth J. Primidone therapy for essential vocal tremor. In: JAMA Otolaryngology – Head and Neck Surgery. 2016; 117–121. DOI: 10.1001/jamaoto.2015.2849
    Back to article
  8. 8Calzetti S, Findley IJ, Pisani F, et al. Phenylethylmalonamide in essential tremor. A double-blind controlled study. J Neurol Neurosurg Psychiatry. 1981; 44: 932–934. DOI: 10.1136/jnnp.44.10.932
    Back to article
  9. 9Findley LJ, Calzetti S. Double-blind controlled study of primidone in essential tremor: Preliminary results. Br Med J. 1982; 285: 608. DOI: 10.1136/bmj.285.6342.608
    Back to article
  10. 10Findley LJ, Cleeves L, Calzetti S. Primidone in essential tremor of the hands and head: A double blind controlled clinical study. J Neurol Neurosurg Psychiatry. 1985; 48: 911–915. DOI: 10.1136/jnnp.48.9.911
    Back to article
  11. 11Koller WC, Royse VL. Efficacy of primidone in essential tremor. Neurology. 1986; 36: 121–124. DOI: 10.1212/WNL.36.1.121
    Back to article
  12. 12Dietrichson P, Espen E. Primidone and propranolol in essential tremor: a study based on quantitative tremor recording and plasma anticonvulsant levels. Acta Neurol Scand. 1987; 75: 332–240. DOI: 10.1111/j.1600-0404.1987.tb05455.x
    Back to article
  13. 13Seyfert S, Hone A, Holl G. Primidone and essential tremor. J Neurol. 1988; 235: 168–170. DOI: 10.1007/BF00314310
    Back to article
  14. 14Sasso E, Perucca E, Calzetti S. Double-blind comparison of primidone and phenobarbital in essential tremor. Neurology. 1988; 38: 808–810. DOI: 10.1212/WNL.38.5.808
    Back to article
  15. 15Sasso E, Perucca E, Fava R, et al. Primidone in the long-term treatment of essential tremor: A prospective study with computerized quantitative analysis. Clin Neuropharmacol. 1990; 13: 67–76. DOI: 10.1097/00002826-199002000-00007
    Back to article
  16. 16Louis ED. The roles of age and aging in essential tremor: An epidemiological perspective. Neuroepidemiology. 2019; 52: 111–118. DOI: 10.1159/000492831
    Back to article
  17. 17Rose SR. Primidone. In: Encyclopedia of Toxicology. Elsevier, 2014; 1066–1067. DOI: 10.1016/B978-0-12-386454-3.00774-0
    Back to article
  18. 18Tanoshima R, ‘t Jong GW, Merlocco A, et al. A Child Exposed to Primidone Not Prescribed for Her. Ther Drug Monit. 2013; 35: 145–149. DOI: 10.1097/FTD.0b013e3182843206
    Back to article
  19. 19Gorman WP, Cooper R, Pocock P, et al. A comparison of primidone, propranolol, and placebo in essential tremor, using quantitative analysis. J Neurol Neurosurg Psychiatry. 1986; 49: 64–68. DOI: 10.1136/jnnp.49.1.64
    Back to article
  20. 20Serrano-Dueñas M. Use of primidone in low doses (250 mg/day) versus high doses (750 mg/day) in the management of essential tremor. Double-blind comparative study with one-year follow-up. Park Relat Disord. 2003; 10: 29–33. DOI: 10.1016/S1353-8020(03)00070-1
    Back to article
  21. 21Ondo WG. Current and Emerging Treatments of Essential Tremor. Neurologic Clinics. 2020; 38: 309–323. DOI: 10.1016/j.ncl.2020.01.002
    Back to article
  22. 22Kutt H. Pharmacodynamic and pharmacokinetic measurements of antiepileptic drugs. Clin Pharmacol Ther. 1974; 16: 243–150. DOI: 10.1002/cpt1974161part2243
    Back to article
  23. 23Crystal HA. Duration of effectiveness of primidone in essential tremor. Neurology. 1986; 36: 1743. DOI: 10.1212/WNL.36.11.1543
    Back to article
  24. 24Ahuja GK, Schumacher GA. Drug-Induced Systemic Lupus Erythematosus: Primidone as a Possible Cause. JAMA J Am Med Assoc. 1966; 198: 669–671. DOI: 10.1001/jama.1966.03110190151046
    Back to article
  25. 25Vasconcellos LFR, Nassif D, Spitz M. Dupuytren, Ledderhose, and Peyronie Diseases after Primidone Use for Essential Tremor. Neurologist. 2019; 24: 150–151. DOI: 10.1097/NRL.0000000000000240
    Back to article
  26. 26Timberlake WH, Abbott JA, Schwab RS. Mysoline; an effective anticonvulsant with initial problems of adjustment. N Engl J Med. 1955; 252: 304–307. DOI: 10.1056/NEJM195502242520803
    Back to article
  27. 27O’Suilleabhain P, Dewey RB. Randomized trial comparing primidone initiation schedules for treating essential tremor. Mov Disord. 2002; 17: 382–386. DOI: 10.1002/mds.10083
    Back to article
  28. 28Leppik IE, Cloyd JC, Miller K. Development of tolerance to the side effects of primidone. Ther Drug Monit. 1984; 6: 189–191. DOI: 10.1097/00007691-198406000-00010
    Back to article
  29. 29Herranz JL, Armijo JA, Arteaga R. Clinical Side Effects of Phenobarbital, Primidone, Phenytoin, Carbamazepine, and Valproate During Monotherapy in Children. Epilepsia. 1988; 29: 794–804. DOI: 10.1111/j.1528-1157.1988.tb04237.x
    Back to article
  30. 30Bonkalo A, Arthurs RG. Mysoline in treatment of epileptic and non-epileptic psychiatric patients. Can Med Assoc J. 1953; 68: 570–574.
    Back to article
  31. 31Nathan PW. Primidone in the treatment of Non-idiopathic epilepsy. Lancet. 1954; 263: 21–23. DOI: 10.1016/S0140-6736(54)90760-6
    Back to article
  32. 32Couston TA. Mysoline’ in the treatment of recalcitrant idiopathic major epilepsy in mentally defective children. Arch Dis Child. 1954; 29: 323–325. DOI: 10.1136/adc.29.146.323
    Back to article
  33. 33Sharpe DS. Primidone in Mental Deficiency Practice. Br Med J. 1954; 2: 627–629. DOI: 10.1136/bmj.2.4888.627
    Back to article
  34. 34Livingston S, Petersen D. Primidone (Mysoline) in the Treatment of Epilepsy. N Engl J Med. 1956; 254: 327–329. DOI: 10.1056/NEJM195602162540706
    Back to article
  35. 35Rettig JH. Chlorpromazine and mysoline in the control of convulsive epilepsy in mentally deficient patients. J Nerv Ment Dis. 1956; 124: 607–611. DOI: 10.1097/00005053-195612000-00008
    Back to article
  36. 36Rodin EA, Rim CS, Kitano H, et al. A comparison of the effectiveness of primidone versus carbamazepine in epileptic outpatients. J Nerv Ment Dis. 1976; 163: 41–46. DOI: 10.1097/00005053-197607000-00006
    Back to article
  37. 37Naderi F, Javadi SA, Motamedi M, et al. The efficacy of primidone in reducing severe cerebellar tremors in patients with multiple sclerosis. Clin Neuropharmacol. 2012; 35: 224–226. DOI: 10.1097/WNF.0b013e31826249bb
    Back to article
  38. 38Mangoni AA, Jackson SHD. Age-related changes in pharmacokinetics and pharmacodynamics: Basic principles and practical applications. British Journal of Clinical Pharmacology. 2004; 57: 6–14. DOI: 10.1046/j.1365-2125.2003.02007.x
    Back to article
  39. 39Kanner AM, Parra J, Frey M. The ‘forgotten’ cross-tolerance between phenobarbital and primidone: It can prevent acute primidone-related toxicity. Epilepsia. 2000; 41: 1310–1314. DOI: 10.1111/j.1528-1157.2000.tb04610.x
    Back to article
  40. 40Gallagher BB, Baumel IP, Mattson RH, et al. Primidone, diphenylhydantoin and phenobarbital: Aspects of acute and chronic toxicity. Neurology. 1973; 23: 145–145. DOI: 10.1212/WNL.23.2.145
    Back to article
  41. 41Salas-Crisóstomo M, Franco-Tormo MJ, Trujillo-Paredes N, et al. Systemic Injections of Primidone Cause Wake-Inducing Effects in Rats. Curr Psychopharmacol. 2019; 8: 72–78. DOI: 10.2174/2211556007666180425143506
    Back to article
  42. 42Musacchio T, Purrer V, Papagianni A, et al. Non-motor symptoms of essential tremor are independent of tremor severity and have an impact on quality of life. Tremor and Other Hyperkinetic Movements. 2016; 6: 361. DOI: 10.5334/tohm.284
    Back to article
  43. 43Louis ED. Non-motor symptoms in essential tremor: A review of the current data and state of the field. Parkinsonism Relat Disord. 2016; 22(Suppl 1): S115–118. DOI: 10.1016/j.parkreldis.2015.08.034
    Back to article
  44. 44Rohl B, Collins K, Morgan S, et al. Daytime sleepiness and nighttime sleep quality across the full spectrum of cognitive presentations in essential tremor. J Neurol Sci. 2016; 371: 24–31. DOI: 10.1016/j.jns.2016.10.006
    Back to article
  45. 45Chandran V, Pal PK, Reddy JYC, et al. Non-motor features in essential tremor. Acta Neurol Scand. 2012; 125: 332–337. DOI: 10.1111/j.1600-0404.2011.01573.x
    Back to article
  46. 46Sengul Y, Sengul HS, Yucekaya SK, et al. Cognitive functions, fatigue, depression, anxiety, and sleep disturbances: assessment of nonmotor features in young patients with essential tremor. Acta Neurol Belg. 2015; 115: 281–287. DOI: 10.1007/s13760-014-0396-6
    Back to article
  47. 47Dowd H, Zdrodowska MA, Radler KH, et al. Prospective Longitudinal Study of Gait and Balance in a Cohort of Elderly Essential Tremor Patients. Front Neurol; 11. Epub ahead of print 2020. DOI: 10.3389/fneur.2020.581703
    Back to article
  48. 48Rao AK, Louis ED. Ataxic gait in essential tremor: A disease-associated feature? Tremor and Other Hyperkinetic Movements; 9. Epub ahead of print 2019. DOI: 10.5334/tohm.507
    Back to article
  49. 49Zhang X, Santaniello S. Role of cerebellar GABAergic dysfunctions in the origins of essential tremor. Proc Natl Acad Sci. 2019; 116: 13592–13601. DOI: 10.1073/pnas.1817689116
    Back to article
  50. 50Jiménez-Jiménez FJ, Alonso-Navarro H, García-Martín E, et al. An Update on the Neurochemistry of Essential Tremor. Curr Med Chem. 2020; 27: 1690–1710. DOI: 10.2174/0929867325666181112094330
    Back to article
  51. 51Gironell A. The GABA Hypothesis in Essential Tremor: Lights and Shadows. Tremor and Other Hyperkinetic Movements. 2014; 4: 254. DOI: 10.5334/tohm.229
    Back to article
  52. 52Louis ED, Faust PL. Essential tremor pathology: neurodegeneration and reorganization of neuronal connections. Nat Rev Neurol. 2020; 16: 69–83. DOI: 10.1038/s41582-019-0302-1
    Back to article
DOI: https://doi.org/10.5334/tohm.672 | Journal eISSN: 2160-8288
Journal RSS Feed
Language: English
Submitted on: Nov 18, 2021
Accepted on: Dec 21, 2021
Published on: Dec 31, 2021
Published by: Ubiquity Press
In partnership with: Paradigm Publishing Services
Publication frequency: 1 issue per year
Keywords:
Essential tremor,
treatment,
primidone,
side effects,
GABA

© 2021 Abhishek Lenka, Elan D. Louis, published by Ubiquity Press
This work is licensed under the Creative Commons Attribution 4.0 License.

Previous articleVolume 11 (2021): Issue 1Next article